Tardif Diskinezi ve Tedavi Yaklaşımları

Abstract

Tardif diskinezi, etiyolojisi tam olarak belirlenememiş bu nedenle kesin bir tedavisi olmayan, kalıcı olabilen, kişinin yaşamını önemli derecede etkileyen, iyatrojenik bir hareket bozukluğudur. Özellikle ağız, dil ve yüzü tutmakla birlikte ekstremite ve gövdede olabilen anormal, istemsiz hareketlerdir. Uzun yıllardır kullanılmakta olan antipsikotik ilaçların kullanımının yaygınlaşması ile ortaya çıkan en önemli yan etkilerinden birisidir. Atipik antipsikotik kullanımı ile birlikte tardif diskinezi görülme sıklığında azalma beklenmekle beraber yeni nesil atipik antipsikotik kullanımında dahi tardif diskinezi görülebilmektedir. Tardif diskinezi tedavisinde ilaçsız izlemden derin beyin stimulasyonuna kadar çeşitli tedavi yöntemleri denenmektedir. Bu yazıda tardif diskinezinin epidemiyolojisi, etiyolojisi, risk faktörleri, patofizyolojisi ve tedavisi gözden geçirilmiştir.

Keywords

• Antipsikotik,tardif diskinezi,yan etki

Tardive Dyskinesia and Treatment Approaches

Abstract

Tardive dyskinesia is an iatrogenic movement disorder with an incompletely determined etiology. Involuntary movements can effect oral, lingual, facial, corporal muscles and can be permanent. Tardive dyskinesia is one of the most important side effects of long term antipsychotic use. There is some decrease in tardive dyskinesia rates after common use of second generation antipsychotics but tardive dyskinesia can be seen even after use of second generation antipsychotics. There are some treatment options from drug-free observation to deep brain stimulation in tardive dyskinesia. The aim of this article is to review epidemiology, etiology, risk factors, pathophysiology and treatment options of tardive dyskinesia.

Keywords

• tardive dyskinesia,side effect,antipsychotic drugs

References

1. Aberg K, Adkins DE, Bukszar J, Webb BT, Caroff SN, Miller DD et al. (2010) Genomewide association study of movement-related adverse antiphychotic effects. Biol Psychiatry, 76:279-282.
2. Alabed S, Latifeh Y, Mohammad HA, Rifai A (2011) Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev, 4:CD000203.
3. APA (1992) Tardive Dyskinesia: A Task Force Report of the American Psychiatric Association. Washington, DC: American Psychiatric Association.
4. APA (2013) Diagnostic and Statistical Manual of Mental Disorders, Fifth edition (DSM-5). Washington DC, American Psychiatric Association.
5. Anand VS, Dewan MJ (1996) Withdrawal-emergent dyskinesia in a patient on risperidone undergoing dosage reduction. Ann Clin Psychiatry, 8:179–182.
6. Anderson KE, Factor SA, Hauser RA (2016) A randomized, double blind, placebo-controlled trial of deutetrabenazine for the treatment of tardive dyskinesia (ARM-TD). Poster presented at: The American Psychiatric Association Annual Meeting; Atlanta, GA.
7. Angus S, Sugars J, Boltezar R, Koskewich S, Schneider NM (1997) A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia. J Clin Psychopharmacol, 17:88–91.
8. Aquino CC, Lang AE (2014) Tardive dyskinesia syndromes: current concepts. Parkinsonism Relat Disord, 20(suppl 1):S113–S117.

9. Ardebili DS, Hosseinzadeh H, Abnous K, Vahdati HF, Yazdian RR, Razavi BM (2015) Involvement of brain-derived neurotrophic factor (BDNF) on malathion induced depressive-like behavior in subacute exposure and protective effects of crocin. Iran J Basic Med Sci, 18:958-966.
10. Barnes TR (1987) The present status of tardive dyskinesia and akathisia in the treatment schizophrenia. Psychiatr Dev, 4:310-319.
11. Bergman J, Dwolatzky T, Brettholz I, Lerner V (2005) Beneficial effect of donepezil in the treatment of elderly patients with tardive movement disorders. J Clin Psychiatry, 66:107-110.
12. Bhidayasiri R, Boonyawairoj S. (2011) Spectrum of tardive syndromes; clinical recognation and management. Postgrad Med J, 87:132-134.
13. Bhidayasiri R, Fahn S, Weiner WJ, Gronseth GS, Sullivan KL, Zesiewicz TA (2013) Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology, 81:463-469.
14. Boucard AA, Chubykin AA, Comoletti D, Taylor P, Sudhof TC (2005) A splice code for trans-synaptic cell adhesion mediated by binding of neuroligin 1 to alpha- and beta-neurexins. Neuron, 48:229–236.
15. Caroff SN, Miller DD, Dhopesh V, Campbell EC (2011) Is there a rational management strategy for tardive dsykinesia? Curr Psychiatry, 10(10):22-32.
16. Chong SA, Sachdev PS (2004) The epidemiology of tardive dyskinesia. In Drug- Induced Movement Disorders (Ed KD Sethi):37-60. New York, Marcel Dekker.
17. Chouinard G, Jones B, Remington G, Bloom D, Addington D, Mac Evan GW et al. (1993) A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol, 13:25–40.
18. Chouinard G (1995) Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. J Clin Psychopharmacol, 15:36-44.
19. Cloud LJ, Zutshi D, Factor SA (2014) Tardive dyskinesia: therapeutic options for an increasingly common disorder. Neurotherapeutics, 11:166-176.
20. Cornett EM, Novitch M, Kaye AD, Kata V, Kaye AM (2017) Medication-ınduced tardive dyskinesia. Ochsner Journal, 17:162–174.
21. Correll CU, Schenk EM (2008) Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry, 21:151–156.
22. Cowen MA, Green M, Bertollo DN, Abbott K (1997) A treatment for tardive dyskinesia and some other extrapyramidal symptoms. J Clin Psychopharmacol, 17:190-193.
23. Csernansky JG, Grabowski K, Cervantes J, Kaplan J, Yesavage JA (1981) Fluphenazine decanoate and tardive dyskinesia: a possible association. Am J Psychiatry, 138:1362-1365.
24. de Araújo DP, Camboim TGM, Silva APM, Silva CDF, de Sousa RC, Barbosa MDA et al. (2017) Behavioral and neurohemical effects of alpha lipoic acid associtated ted with omega 3 in tardive dyskinesia ınduced by chronical haloperidol in rats. Can J Physiol Pharmacol, 95:837-843.
25. Defeudis FV (1991) Ginkgo biloba Extract (EGb): Pharmacological Activities and Clinical Applications. Paris, Elsevier.
26. Dixon L, Weiden PJ, Haas G, Sweeney J, Frances AJ (1992) Increased tardive dyskinesia in alcohol- abusing schizophrenic patients. Compr Psychiatry, 33:121-122.
27. Egan MF, Aput J, Wyatt RJ (1997) Treatment of tardive dyskinesia. Schizopr Bull, 23:583-609.
28. Eltahawy HA, Feinstein A, Khan F, Saint-Cyr J, Lang AE, Lozano AM (2004) Bilateral globus pallidus internus deep brain stimulation in tardive dyskinesia: a case report. Mov Disord, 19:969-972.
29. Ertugrul A, Demir B (2005) Clozapine-induced tardive dyskinesia: a case report. Prog Neuropsychopharmacol Biol Psychiatry, 29:633-635.
30. Faurbye A, Rasch PJ, Petersen PB, Brandborg G, Pakkenberg H (1964) Neurological symptoms in pharmacotherapy of psychoses. Acta Psychiatr Scand, 40:10-27.
31. Fei H, Grygoruk A, Brooks ES, Chen A, Krantz DE (2008) Trafficking vesicular neurotransmitter transporters. Traffic, 9:1425–1436.
32. Fernandez HH, Friedman JH (2003) Classification and treatment of tardive syndreomes. Neurologist, 9:16-27.
33. Franzini A, Marras C, Ferroli P, Zorzi G, Bugiani O, Romito L et al. (2005) Long-term high frequency bilateral pallidal stimulation for neuroleptic-induced tardive dystonia. report of two cases. J Neurosurg, 102:721–725.
34. Ganzini L, Heintz RT, Hoffman WF, Casey DE (1991) The prevalence of tardive dyskinesia in neuroleptic treated diabetics: a controlled study. Arch Gen Psychiatry, 48:259-263.
35. Gerlach J (1985) Pathophysiological mechanisms underlying tardive dyskinesia. Acta Psychiatr Scand, 77:369-378.
36. Goetz CG (1997) Tardive dyskinesias. In Movement Disorders: Neurologic Principles and Practice (Eds RL Watt, WC Koller):519-526. New York, McGraw-Hill.
37. Hahn CG, Wang HY, Cho DS, Talbot K, Gur RE, Berrettini WH et al. (2006) Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nat Med, 12:824-828.
38. Hatcher-Martin JM, Armstrong KA, Scorr LM, Factor SA (2016) Propranolol therapy for tardive dyskinesia: a retrospective examination. Parkinsonism Relat Disord, 32:124-126.
39. Heitzmann E, Javelot H, Weiner L, Michel B (2016) A case of aripiprazole-induced tardive dyskinesia with dramatic evolution. Case Rep Psychiatry, 2016:7031245.
40. Hori H, Ohmori O, Shinkai T, Kojima H, Nakamura J (2001) Association between three functional polymorphisims of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia. Am J Med, 105:774-778.
41. Hugenholtz GW, Heerdink ER, Stolker JJ, Meijer WE, Egberts AC, Nolen WA (2006) Haloperidol dose when used as active comparator in randomized controlled trials with atypical antipsychotics in schizophrenia: comparison with officially recommended doses. J Clin Psychiatry, 67:897-903.
42. Hyde TM, Apud JA, Fisher WC, Egan MF (2008) Tardive dyskinesia. In Drug Induced Movement Disorders, 2nd edition (Eds SA Faktor, AE Lang, WJ Weiner):213-256. n, Massachusetts, Blackwell Futura.
43. Imenshahidi M, Zafari H, Hosseinzadeh H (2011) Effects of crocin on the acquisition and reinstatement of morphine-induced conditioned place preference in mice. Pharmacologyonline, 1:1007-1013.
44. Josiassen RC, Remington G, Burke J (2016) Valbenazine (NBI-98854) is effective for treating tardive dyskinesia in individuals with schizophrenia or mood disorder. Poster presented at American Psychiatric Association Annual Meeting, Atlanta,GA.
45. Kamyar M, Razavi BM, Hasani FV, Mehri S, Forountanfar A, Hosseinzadeh H (2016) Crocin prevents haloperidol-induced orofacial dyskinesia: possible an antioxidant mechanism. Iran J Basic Med Sci, 19:1070-1079.
46. Kane JM (2004) Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence. J Clin Psychiatry, 65(suppl 9):16–20.
47. Kane JM, Smith JM (1982) Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry, 39:473-481.
48. Kang NR, Kim MD (2011) Tardive dyskinesia: treatment with aripiprazole. Clin Psychopharmacol Neurosci, 9:1-8.
49. Kaspar R, Ellingrod VL (2014) Strategies for managing tardive dyskinesia. Curr Psychiatry, 13(3):44-46.
50. Kato T, Abe Y, Sotoyama H, Kakita A, Kominami R, Hirokawa S et al. (2011) Transient exposure of neonatal mice to neuregulin-1 results in hyperdopaminergic states in adulthood: implication in neurodevelopmental hypothesis for schizophrenia. Mol Psychiatry, 16:307-320.
51. Kaur N, Kumar P, Jamwal S, Deshmukh R, Gauttam V (2016) Tetrabenazine: spotlight on drug review. Ann Neurosci, 23:176–185.
52. Kefalopoulou Z, Paschali A, Markaki E, Vassilakos P, Ellul J, Constantoyannis C (2009) A double-blind study on a patient with tardive dyskinesia treated with pallidal deep brain stimulation. Acta Neurol Scand, 119:269–273.
53. Kelly DL, Weiner E, Ball MP, McMahon RP, Carpenter WT, Buchanan RW (2009) Remission in schizophrenia: the relationship to baseline symptoms and changes in symptom domains during a one-year study. J Psychopharmacol, 23:436-441.
54. Kılıç A, Erten E, Özdemir A (2015) Ketiapin ve olanzapin tedavisi sırasında ortaya çıkan Meigs sendromu ve blefarospazm. Noro Psikiyatr Ars, 52:207-209.
55. Kim J, Macmaster E, Schwartz TL (2014) Tardive dyskinesia in patients treated with atypical antipsychotics: case series and brief review of etiologic and treatment considerations. Drugs Context, 3:212259.
56. Kiriakakis V, Bhatia KP, Quinn NP, Marsden CD (1998) The natural history of tardive dystonia: a long-term follow-up study of 107 cases. Brain J Neurol, 121:2053–2066.
57. Kosel M, Sturm V, Frick C, Lenartz D, Zeidler G, Brodesser D et al. (2007) Mood improvement after deep brain stimulation of the internal globus pallidus for tardive dyskinesia in a patient suffering from major depression. J Psychiatr Res, 41:801-803.
58. Kulkarni SK, Naidu PS. (2003) Pathophysiology and drug therapy of tardive dyskinesia: current concepts and future perspectives. Drugs Today (Barc), 39:19-49.
59. Kundakçı T (1998) Geç diskinezili ve dirençli bir katotonik şizofreni olgusunda klozapin tedavisi. Klinik Psikofarmakol Bulteni, 8:40-42.
60. Lanning R, Lett TA, Tiwari AK, Brandl EJ, de Luca V, Voineskos AN et al. (2017) Association study between the neurexin-1 gene and tardive dyskinesia. Hum Psychopharmacol, doi:10.1002/hup.2568.
61. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO et al. (2004) Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry, 161:1-56.
62. Lehosit JB, Pirmohamed F, Vijayakumar D, Cloud LJ (2015) Tardive dyskinesia. eLS, 1–7.
63. Lerer B, Segman RH, Fangerau H, Daly AK, Basile VS, Cavallaro R et al. (2002) Pharmacogenetics of tardive dyskinesia: Combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphisim. Neuropsychopharmacology, 27:105-119.
64. Lerner V, Miodownik C, Kaptsan A, Bersudsky Y, Libov I, Sela BA et al. (2007) Vitamin B6 treatment for tardive dyskinesia: a randomized, double-blind, placebocontrolled, crossover study. J Clin Psychiatry, 68:1648-1654.
65. Leung JG, Breden EL (2011) Tetrabenazine for the treatment of tardive dyskinesia. Ann Pharmacother, 45:525–531.
66. Libov I, Miodownik C, Bersudsky Y, Dwolatzky T, Lerner V (2007) Efficacy of piracetam in the treatment of tardive dyskinesia in schizophrenic patients: a randomized, double-blind, placebo-controlled crossover study. J Clin Psychiatry, 68:1031-1037.
67. Lise MF, El-Husseini A (2006) The neuroligin and neurexin families: from structure to function at the synapse. Cell Mol Life Sci, 63:1833–1849.
68. Lohr JB, Kuczenski R, Niculescu AB (2003) Oxidative mechanisms and tardive dyskinesia. CNS Drugs, 17:47-62.
69. Loonen AJ, Ivanova SA (2013) New insights into the mechanism of drug-induced dyskinesia. CNS Spectr, 18:15–20.
70. Magarinos-Ascone CM, Regidor I, Gómez-Galán M, Cabanes-Martínez L, Figueiras-Méndez R (2008) Deep brain stimulation in the globus pallidus to treat dystonia: electrophysiological characteristics and 2 years’ follow-up in 10 patients. Neuroscience,152:558–571.
71. Margolese HC, Chouinard G, Kolivakis TT, Beyclair L, Miller R (2005) Tardive dsykinesia in the era of typical and atypical antipsychotics. Part1: pathophysiology and mechanisms of induction. Can J Psychiatry, 50:541-547.
72. McGavin CL, John V, Musser WS (2003) Levetiracetam as a treatment for tardive dyskinesia: a case report. Neurology, 61:419.
73. Mei L, Xiong WC (2008) Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. NatRev Neurosci, 9:437-452.
74. Meyer JM (2016) Forgotten but not gone: new developments in the understanding and treatment of tardive dyskinesia. CNS Spectr, 21(S1):13-24.
75. Meyer JM (2017) Deutetrabenazine for tardive dyskinesia. Curr Psychiatry, 16(10):35-41.
76. Miller DD, Caroff SN, Davis SM, Rosenheck RA, McEvoy JP, Saltz BL et al. (2008) Extrapyramidal side-effects of antipsychotics in a randomised trial. Br J Psychiatry, 193:279-288.
77. Miodownik C, Meoded A, Libov I, Bersudsky Y, Sela B, Lerner V (2008). Pyridoxal plasma level in schizophrenia and schizoaffective patients with and without tardive dyskinesia. Clin Neuropharmacol, 31:197–203.
78. Mitchell IJ, Crossman AR, Liminga U, Andren P, Gunne LM (1992) Regional changes in 2-deoxyglucose uptake associatiod with neuropeptic-induced tardive dsykinesia in the Cebus monkey. Mov Disord, 7:32-37.
79. Morigaki R, Mure H, Kaji R, Nagahiro S, Goto S (2016) Therapeutic perspective on tardive syndrome with special reference to deep brain stimulation. Front Psychiatry, 7:207.
80. Muller T (2015) Valbenazine granted breakthrough drug status for treating tardive dyskinesia. Expert Opin Investig Drugs, 24:737–742.
81. Muscettola G, Pampallona S, Barbato G, Casiella M, Bollini P (1993) Persistent tardive dyskinesia: demographic and pharmacological risk factors. Acta Psychiatr Scand, 87:29-36.
82. Nalbant A, Can A, Burhan HS, Cansiz A, Yavuz KF, Delice MS et al. (2016) Tardive dyskinesia in long term hospitalized patients with schizophrenia. Dusunen Adam, 29:259-265.
83. Nandi D, Parkin S, Scott R, Winter JL, Joint C, Gregory R et al. (2002) Camptocormia treated with bilateral pallidal stimulation: case report. Neurosurg Focus, 12:1–6.
84. Novak G, Gallo A, Zai CC, Meltzer HY, Lieberman JA, Potkin SG et al. (2010) Association of orphan nuclear receptor NR4A1 with tardive dsykinesia. Psychiatr Genet, 20:39-43.
85. O’Brien A (2015) Comparing the risk of tardive dyskinesia in older adults with first-generation and second-generation antipsychotics: a systematic review and meta-analysis. Int J Geriatr Psychiatry, 31:683-693.
86. Obeso JA (2016) The Movement Disorders journal 2016 and onward. Mov Disord, 31:1–2.
87. Öztürk O, Kurt E, Oral T (2006) İlaca bağlı geç başlangıçlı hareket bozuklukları. Klinik Psikofarmakol Bülteni, 16:263-273.
88. Quik M, Zhang D, Perez XA, Bordia T (2014) Role for the nicotinic cholinergic system in movement disorders; therapeutic implications. Pharmacol Ther, 144:50-59.
89. Pinninti NR, Faden J, Adityanjee A (2015) Are second-generation antipsychotics useful in tardive dystonia? Clin Neuropharmacol, 38:183-197.
90. Pouchet-Courtemanche H, Rouaud T, Thobois S, Nguyen JM, Brefel-Courbon C, Chreau I et al. (2016) Long-term efficacy and tolerability of bilateral pallidal stimulation to treat tardive dyskinesia. Neurology, 86:651–659.
91. Pretto TE, Dalvi A, Kang UJ, Penn RD (2008) A prospective blinded evaluation of deep brain stimulation for the treatment of secondary dystonia and primary torticollis syndromes. J Neurosurg, 109:405-409.
92. Rana AQ, Chaudry ZM, Blanchet PJ (2013) New and emerging treatments for symptomatic tardive dyskinesia. Drug Des Devel Ther, 7:1329-1340.
93. Reissner C, Klose M, Fairless R, Missler M (2008) Mutational analysis of the neurexin/neuroligin complex reveals essential and regulatory components. Proc Natl Acad Sci U S A, 105:15124–15129.
94. Revuelta GJ, Cloud L, Aia PG, Factor SA (2012) Hyperkinetic Movement Disorders: Differential Diagnosis and Treatment. Chichester, Wiley-Blackwell.
95. Rosenheck R, Perlick D, Bingham S, Liu-Mares W, Collins J, Warren S et al. (2003) Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA, 290:2693–2702.
96. Rosenheck RA (2007) Evaluating the cost-effectiveness of reduced tardive dyskinesia with second-generation antipsychotics. Br J Psychiatry, 191:238–245.
97. Sachdev P (1992) Drug-induced movement disorders in institutionalized adults with mental retardation: clinical characteristics and risk factors. Aust N Z J Psychiatry, 26:242-248.
98. Sachdev PS (2000) The current status of tardive dyskinesia. Aust N Z J Psychiatry, 34:355-369.
99. Sako W, Goto S, Shimazu H, Murase N, Matsuzaki K, Tamura T et al. (2008) Bilateral deep brain stimulation of the globus pallidus internus in tardive dystonia. Mov Disord, 23:1929–1931.
100. Salem H, Pigott T, Zhang XY, Zeni CP, Teixeira AL (2017) Antipsychotic-Induced tardive dyskinesia: from biological basis to clinical management. Expert Rev Neurother, 17:883-894.
101. Schonecker M (1957) Paroxysmal dyskinesia as the effect of megaphen. Nervenarzt, 28:550-553.
102. Schooler NR, Kane JM (1982) Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry, 39:486-487.
103. Schrader C, Peschel T, Petermeyer M, Dengler R, Hellwig D (2004) Unilateral deep brain stimulation of the internal globus pallidus alleviates tardive dyskinesia. Mov Disord, 19:583-585.
104. Sharma A, Ramaswamy S, Dewan VK (2005) Resolution of ziprasidone related tardive dyskinesia with a switch to aripiprazole. Prim Care Companion J Clin Psychiatry, 7:36.
105. Shen V, Clarence-Smith K, Hunter C, Jankovic J (2013) Safety and efficacy of tetrabenazine and use of concomitant medications during longterm, open-label treatment of chorea associated with Huntington’s and other diseases. Tremor Other Hyperkinet Mov (NY), 3:03-191-4337-1.
106. Shi J, Tan YL, Wang ZR, An HM, Li J, Wang YC et al. (2016) Ginkgo biloba and vitamin E ameliorate haloperidol-induced vacuous chewingmovement and brain-derived neurotrophic factor expression in a rat tardive dyskinesia model. Pharmacol Biochem Behav, 148:53–58.
107. Shireen E (2016) Experimental treatment of antipsychotic-induced movement disorders. J Exp Pharmacol, 8:1-10.
108. Silvestri S, Seeman MV, Negrete JC, Houle S, Shammi CM, Remington GJ et al. (2000) Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology (Berl), 152:174–180.
109. Smith JM, Baldessarini RJ (1980) Changes in prevalence, severity and recovery in tardive dyskinesia with age. Arch Gen Psychiatry, 37:1368-1373.
110. Stacy M, Jankovic J (1991) Tardive dyskinesia. Curr Opin Neurol Neurosurg, 4:343-349.
111. Tarsy D, Baldessarini RJ (2006) Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Mov Disord, 21:589-598.
112. Thaker GK, Nguyen JA, Strauss ME, Jacobson R, Kaup BA, Tamminga CA (1990) Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. Am J Psychiatry, 147:445-451.
113. Thobois S, Ballanger B, Xie-Brustolin J, Damier P, Durif F, Azulay JP et al. (2008) Globus pallidus stimulation reduces frontal hyperactivity in tardive dystonia. J Cereb Blood Flow Metab, 28:1127–1138.
114. Trottenberg T, Paul G, Meissner W, Maier-Hauff K, Taschner C, Kupsch A (2001) Pallidal and thalamic neurostimulation in severe tardive dystonia. J Neurol Neurosurg Psychiatry, 70:557–559.
115. Tschopp L, Salazar Z, Micheli F (2009) Botulinum toxin in painful tardive dyskinesia. Clin Neuropharmacol, 32:165-166.
116. Tufan AE, Bilici R, Uğurlu GK, Yılmaz S, Erdoğan A (2013) Psikotik bir ergen hastada olanzapine bağlı tardif diskinezi ve klozapin ile tedavisi. Noro Psikiyatr Ars, 50:183-185.
117. Tuman TC, Çakır U, Yıldırım O, Camkurt MA (2017) Tardive dyskinesia associated with bupropion. Clin Psychopharmacol Neurosci, 15:194-196.
118. Turrone P, Remington G, Kapur S, Nobrega JN (2003) The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats. Psychopharmacology (Berl), 165:166–171.
119. Vernon GM (1991) Drug-induced and tardive movement disorders. Neurosci Nurs, 23:183-187.
120. Vijayakumar D, Jankovic J (2016) Drug-induced dyskinesia, part 2: treatment of tardive dyskinesia. Drugs, 76:779-787.
121. Waln O, Jankovic J (2013) An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov (NY), 3:tre-03-161-4138-1.
122. Weiner WJ, Lang AE (1989) Movement Disorders: A Comprehensive Survey. Mount Kisco, Futura Publishing.
123. Wirshing DA, Bartzokis G, Pierre JM, Wirshing WC, Sun A, Tishler TA et al. (1998) Tardive dyskinesia and serum iron indices. Biol Psychiatry, 44:493-498.
124. Witter DP, Holbert RC, Suryadevara U (2017) Pharmacotherapy for the treatment of tardive dyskinesia in schizophrenia patients. Expert Opin Pharmacother, 18:965-972.
125. Wonodi I, Adami HM, Cassady SL, Sherr JD, Avila MT, Thaker GK (2004) Ethnicity and the course of tardive dyskinesiain outpatients presenting to the motor disorders clinic at the Maryland psychiatric research center. J Clin Psychopharmacol, 24:592-598.
126. Woods SW, Morgenstern H, Saksa JR, Walsh BC, Sullivan MC, Money R et al. (2010) Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. J Clin Psychiatry, 71:463-474.
127. Woods SW, Saksa JR, Baker CB, Cohen SJ, Tek C (2008) Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry, 69:546-554.
128. Yassa R, Jeste DV (1992) Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr Bull, 18:701-715.
129. Yianni J, Bain P, Giladi N, Auca M, Gregory R, Joint C et al. (2003) Globus pallidus internus deep brain stimulation for dystonic conditions: a prospective audit. Mov Disord, 18:436–442.
130. Yüksel N (1998) Antipsikotik ilaçlar. Ankara, Bilimsel Tıp Yayınevi.
131. Zai CC, Tiwari AK, Chowdhury NI, Yilmaz Z, de Luca V, Müller DJ et al. (2017) Genetic study of Neuregulin 1 and Receptor tyrosine-protein kinase erbB-4 in tardive dyskinesia. World J Biol Psychiatry, 10:1-5.